Focal nodular hyperplasia

Summary

Focal nodular hyperplasia (MONDO:0100549) is a disease and 3 clinical trials. Top therapeutic interventions include perflubutane. A subtype of hepatobiliary benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	focal nodular hyperplasia
Mondo ID	MONDO:0100549
Is cancer (heuristic)	no

Also known as: FNH · focal nodular hyperplasia of the liver · hepatic focal nodular hyperplasia

Disease family

This is a subtype of hepatobiliary benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › benign digestive system neoplasm › hepatobiliary benign neoplasm › focal nodular hyperplasia

Related subtypes (3): liver lipoma, liver hemangioma, liver leiomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02156700	Not specified	COMPLETED	Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors
NCT02737865	Not specified	COMPLETED	Superb Microvascular Imaging in Focal Nodular Hyperplasia
NCT07153783	Not specified	COMPLETED	Interventional AI-Human Collaboration for Liver Tumor Diagnosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PERFLUBUTANE	3	1